We provide products and services to ophthalmologists. Helping to restore sight compromised by cataracts is our Singular Focus.Read More
Our mission is to provide innovative devices and services in key strategic segments to help you elevate your quality of care and business efficiencies.Read More
HOYA Surgical Optics is different. We’re Globally Powered, a leading ophthalmic device company with a strong entrepreneurial spirit and a dedication to improving both patient outcomes and practice results.Read More
HOYA to invest in InnFocus, Inc., a new glaucoma device company. InnFocus also announced that it received authorization from the FDA to begin Phase I trial of the InnFocus MicroShunt™ to treat open angle glaucoma.
HOYA Surgical Optics announced that it has completed the installation and validation of new equipment at its factory in Singapore and resumed manufacturing of the 1-Piece IOLs that were voluntarily recalled.
HOYA Surgical Optics announced a voluntary recall of NY-60, iSert® 250, iSert® 251, Toric 311, and iSert® Toric 351 IOLs
HOYA Surgical Optics announced that it has received higher than expected reported rates of inflammation and/or endophthalmitis from doctors using iSert® 250, iSert® 251, and NY-60 IOLs in a few countries.
Pharmaceutical Executive magazine’s January 2013 issue includes a country report for Singapore and features remarks by Thomas A. Dunlap, President & CEO of HOYA Surgical Optics.
HOYA Surgical Optics announced today the opening of its new global headquarters in Singapore. In an open house launch event at the new headquarters attended by ophthalmologists, business partners, and local officials, Thomas A. Dunlap, President and CEO of HOYA Surgical Optics, said: “Our business has grown rapidly and become more globally integrated.”